Margetuximab - MacroGenics
Alternative Names: Anti-HER2-monoclonal-antibody-Green-Cross; MARGENZA; Margetuximab-cmkb; MGAH-22Latest Information Update: 07 Jun 2024
At a glance
- Originator Raven biotechnologies
- Developer GC Biopharma; Green Cross; MacroGenics; Merck Sharp & Dohme; ZAI Lab
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Natural killer cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed HER2 positive breast cancer
- Discontinued Bladder cancer; Gastric cancer; Haematological malignancies; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Solid tumours
Most Recent Events
- 14 May 2024 Margetuximab is no longer licensed to Zai Labs in China, Hong Kong, Macau and Taiwan
- 27 Feb 2024 Discontinued - Phase-I for Haematological malignancies (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in Australia, Hong Kong, Ukraine, USA, Thailand, Spain, Poland, Bulgaria (IV)
- 27 Feb 2024 Discontinued - Phase-I for Solid tumours (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in Hong Kong, Australia, Spain, Poland, Bulgaria, Thailand, USA, Ukraine (IV)